Real-world outcomes of lurasidone augmentation for treatment-resistant bipolar depression: a retrospective observational analysis
Lurasidone appears to be an effective and generally well-tolerated adjunctive option for TRBD. However, remission rates remained low, underscoring the need for further research. In this perspective, lurasidone may contribute to more individualized treatment strategies for difficult-to-treat patients, although confirmatory studies are required to better define its role within precision psychiatry.
Authors
- Giuseppe Maina (ORCID: https://orcid.org/0000-0002-2533-140X)
- Gianluca Rosso (ORCID: https://orcid.org/0000-0002-2308-9146)
- Vassilis Martiadis (ORCID: https://orcid.org/0000-0002-3344-1000)
- Giorgia Porceddu (ORCID: https://orcid.org/0000-0001-8315-1602)
- Enrico Pessina (ORCID: https://orcid.org/0000-0003-0485-6319)
- Carlo Ignazio Cattaneo (ORCID: https://orcid.org/0000-0002-6930-8105)
- Carolina Bianca
Institutions
- Regione Campania (IT)
- Ospedale degli Infermi (IT)
- Ospedale San Luigi Gonzaga (IT)
- University of Turin (IT)
- Massachusetts Department of Mental Health (US)
Publication Details
- Journal
- Frontiers in Psychiatry
- Published
- 2026-02-19
- DOI
- https://doi.org/10.3389/fpsyt.2026.1744056
- Primary Topic
- Bipolar Disorder and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00